Skip to contentH
Halozyme Therapeutics, Inc.
H
HALOHalozyme Therapeutics, Inc. Q4 2017 · 10-K
Revenue$189.56M$189.56M+386.0% vs Q4 2016 Net Income$123.88M$123.88MN/M vs Q4 2016 EPS Diluted$850.00$850.00+2,833,233.3% vs Q4 2016 Gross Profit$5,105,000−5.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR
derived
Operating Cash Flowderived$153,249,000N/M Free Cash Flowderived$152,389,000N/M Margins · derivedGross margin2.7%−11.2 pt vs Q4 2016
Operating margin66.4%+124.3 pt vs Q4 2016
Net margin65.4%+135.6 pt vs Q4 2016
ended Dec 31, 2017 · filed Feb 20, 2018 · 51 d after period end